Advanced search
Publication Cover
Future Cardiology Volume 4, 2008 - Issue 1
Submit an article Journal homepage
164
Views
0
CrossRef citations to date
0
Altmetric
Review

Monitoring Antiplatelet Therapy with Point-of-Care Platelet Function Assays: A Review of the Evidence

Jochem W van Werkuma St Antonius Center for Platelet Function ResearchKoekoekslaan 13435 CMNieuwegeinThe Netherlands. Tel: +31 306 099 111; Fax: +31 306 034 420;[email protected]
,
Christian M Hackengb St Antonius Center for Platelet Function ResearchKoekoekslaan 13435 CMNieuwegeinThe Netherlands. Tel: +31 306 099 111; Fax: +31 306 034 420;[email protected]
,
Jaap-Jan J Smitc Isala Klinieken Department of CardiologyZwolle Groot Wezenland 208011 JWZwolleThe Netherlands. Tel: +31 384 242 198; Fax: +31 384 243 222;[email protected]
,
Arnoud WJ van‘t Hofd Isala Klinieken Department of CardiologyZwolle Groot Wezenland 208011 JWZwolleThe Netherlands. Tel: +31 384 242 198; Fax: +31 384 243 222;[email protected]
,
Freek WA Verheugte University Medical Center St Radboud Department of Cardiology PO Box 9101NijmegenThe Netherlands. Tel: +31 243 614 220; Fax: +31 243 540 537;[email protected]
&
Jurriën M ten Bergf St Antonius Center for Platelet Function ResearchKoekoekslaan 13435 CMNieuwegeinThe Netherlands. Tel: +31 306 099 111; Fax: +31 306 034 420;[email protected]
Pages 33-55 | Published online: 18 Dec 2007

Bibliography

  • Azuma H , IshikawaM, SekizakiS: Endothelium-dependent inhibition of platelet aggregation.Br. J. Pharmacol., 88(2), 411–415 (1986).
  • Radomski MW , PalmerRM, MoncadaS: The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide.Br. J. Pharmacol., 92(3), 639–646 (1987).
  • Michelson AD , BenoitSE, FurmanMIet al.: Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am. J. Physiol., 270(5 Pt 2), H1640–H1648 (1996).
  • Sugimoto M , TsujiS, KuwaharaMet al.: Shear-dependent functions of the interaction between soluble von Willebrand factor and platelet glycoprotein Ib in mural thrombus formation on a collagen surface. Int. J. Hematol., 69(1), 48–53 (1999).
  • Wu YP , VinkT, SchiphorstMet al.: Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor–glycoprotein Ib interaction and inhibited by von Willebrand factor–glycoprotein IIb/IIIa interaction. Arterioscler. Thromb. Vasc. Biol., 20(6), 1661–1667 (2000).
  • Nurden AT , NurdenP: A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction.Baillieres Clin. Haematol., 6(3), 653–690 (1993).
  • Shattil SJ : Integrins: dynamic scaffolds for adhesion and signaling in platelets.Blood, 104, 1606–1615 (2006).
  • Kato K , KanajiT, RussellSet al.: The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood, 102, 1701–1707 (2003).
  • Reed G : Platelet secretory mechanisms.Semin. Thromb. Haemost., 30, 441–450 (2004).
  • A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). CAPRIE Steering Committee. Lancet, 348(9038), 1329–1339 (1996).
  • Mehta SR , YusufS, PetersRJet al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 358(9281), 527–533 (2001).
  • Steinhubl SR , BergerPB, MannJTet al. 3rd : Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 288(19), 2411–2420 (2002).
  • Yusuf S , ZhaoF, MehtaSR, ChrolaviciusS, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 345(7), 494–502 (2001).
  • Muller I , BestaF, SchulzC, MassbergS, SchonigA, GawazM: Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.Thromb. Haemost., 89(5), 783–787 (2003).
  • Matetzky S , ShenkmanB, GuettaVet al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 109(25), 3171–3175 (2004).
  • Cuisset T , FrereC, QuiliciJet al.: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost., 4(3), 542–549 (2006).
  • Gurbel PA , BlidenKP, GuyerKet al.: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol., 46(10), 1820–1826 (2005).
  • Hochholzer W , TrenkD, FischerBet al.: Impact of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol., 48(9), 1742–1750 (2006).
  • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med., 330(14), 956–961 (1994).
  • Boersma E , HarringtonRA, MoliternoDJ, WhiteH, SimoonsML: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.Lancet, 360(9329), 342–343 (2002).
  • Boersma E , HarringtonRA, MoliternoDJet al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 359(9302), 189–198 (2002).
  • Boersma E , AkkerhuisKM, TherouxP, CaliffRM, TopolEJ, SimoonsML: Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.Circulation, 100(20), 2045–2048 (1999).
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N. Engl. J. Med., 336(24), 1689–1696 (1997).
  • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet, 352(9122), 87–92 (1998).
  • Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation, 96(5), 1445–1453 (1997).
  • Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med., 338(21), 1488–1497 (1998).
  • Montalescot G , BarraganP, WittenbergOet al.: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med., 344(25), 1895–1903 (2001).
  • Van‘t Hof AW , ErnstNet al., de Boer MJ : Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur. Heart J., 25(10), 837–846 (2004).
  • Batchelor WB , TollesonTR, HuangYet al.: Randomized Comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet Aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation, 106(12), 1470–1476 (2002).
  • Steinhubl SR , Kottke-MarchantK, MoliternoDJet al.: Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation, 100(19), 1977–1982 (1999).
  • Weiss EJ , BrayPF, TaybackMet al.: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N. Engl. J. Med., 334(17), 1090–1094 (1996).
  • Holmes MB , KabbaniSS, TerrienCM, WatkinsMW, SobelBE, SchneiderDJ: Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab.Coron. Artery Dis., 12(3), 245–253 (2001).
  • Holmes MB , SobelBE, SchneiderDJ: Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects.Am. J. Cardiol., 84(2), 203–207 (1999).
  • Tcheng JE , EllisSG, GeorgeBSet al.: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation, 90(4), 1757–1764 (1994).
  • Hobbach HP , SchusterP: Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.Z. Kardiol., 92(3), 213–218 (2003).
  • Simon DI , LiuCB, GanzPet al.: A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter. Cardiovasc. Interv., 52(4), 425–432 (2001).
  • Barrett JS , MurphyG, PeerlinckKet al.: Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin. Pharmacol. Ther., 56(4), 377–388 (1994).
  • Harrington RA , KleimanNS, Kottke-MarchantKet al.: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol., 76(17), 1222–1227 (1995).
  • Van Cott EM , FletcherSR, KratzA: Effects of the blood-collection tube material and long-term storage on platelet activation parameters on the ADVIA 120/2120 hematology system.Lab. Hematol., 11(1), 71–75 (2005).
  • Van Cott EM , LewandrowskiKB, PatelSet al.: Comparison of glass K3EDTA versus plastic K2EDTA blood-drawing tubes for complete blood counts, reticulocyte counts, and white blood cell differentials. Lab. Hematol., 9(1), 10–14 (2003).
  • Mani H , KirchmayrK, KlafflingCet al.: Influence of blood collection techniques on platelet function. Platelets, 15(5), 315–318 (2004).
  • Mani H , LuxembourgB, KlafflingC, ErbeM, Lindhoff-LastE: Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements.J. Clin. Pathol., 58(7), 747–750 (2005).
  • Breddin HK , ZiemenH, BauerOet al.: Time and temperature dependent changes of ADP – and collagen-induced and “spontaneous” aggregation. Thromb. Res., 19(4–5), 621–638 (1980).
  • Patel P , GonzalesR, DokainishH, LakkisN: Impact of adenosine diphosphate and calcium chelation on platelet aggregation testing in patients receiving clopidogrel therapy.J. Am. Coll. Cardiol., 47(2), 464–465 (2006).
  • Phillips DR , TengW, ArfstenAet al.: Effect of Ca2+ on GP IIb–IIa interactions with integrilin: enhanced GP IIb–IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation, 96(5), 1488–1494 (1997).
  • Marciniak SJ Jr, Jordan RE, Mascelli MA: Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb. Haemost., 85(3), 539–543 (2001).
  • Labarthe B , TherouxP, AngioiM, Ghitescu M: Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J. Am. Coll. Cardiol., 46(4), 638–645 (2005).
  • Storey RF , MayJA, HeptinstallS: Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.Thromb. Res., 115(4), 301–307 (2005).
  • Mascelli MA , KleimanNS, MarciniakSJ Jr, Damaraju L, Weisman HF, Jordan RE: Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am. Heart J., 139(4), 696–703 (2000).
  • Gawaz M , NeumannFJ, OttI, SchiesslerA, SchomigA: Platelet function in acute myocardial infarction treated with direct angioplasty.Circulation, 93(2), 229–237 (1996).
  • Gurbel PA , SamaraWM, BlidenKP: Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.Platelets, 15(2), 95–99 (2004).
  • Soffer D , MoussaI, HarjaiKJet al.: Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter. Cardiovasc. Interv., 59(1), 21–25 (2003).
  • Gurbel PA , BlidenKP, HayesKM, YohoJA, HerzogWR, TantryUS: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.J. Am. Coll. Cardiol., 45(9), 1392–1396 (2005).
  • O‘Brien JR , ShoobridgeSM, FinchWJ: Comparison of the effect of heparin and citrate on platelet aggregation.J. Clin. Pathol., 22, 28–31 (1969).
  • Warlow C , OgstonD, DouglasAS: The relationship between platelet aggregation and the time interval after venipuncture.Thromb. Diath. Haemorrh., 31, 133–141 (1974).
  • Hayward CP , EikelboomJ: Platelet function testing: quality assurance.Semin. Thromb. Hemost., 33(3), 273–282 (2007).
  • Born GV , DearnleyR, FoulksJG, Sharp DE: Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors. J. Physiol, 280, 193–212 (1978).
  • Born GV : Aggregation of blood platelets by adenosine diphosphate and its reversal.Nature, 194, 927–929 (1962).
  • Sixma JJ : Methods for platelet aggregation. In: Platelet Function and Thrombosis, Vol. 34. Mannucci PM GS (Ed.). Plenum Press, NY, USA, 79 (1972).
  • Riess H , BraunG, BrehmG, HillerE: Critical evaluation of platelet aggregation in whole human blood.Am. J. Clin. Pathol., 85(1), 50–56 (1986).
  • Gum PA , ThamilarasanM, WatanabeJ, BlackstoneEH, LauerMS: Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis.JAMA, 286(10), 1187–1194 (2001).
  • Gum PA , Kottke-MarchantK, WelshPA, WhiteJ, TopolEJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.J. Am. Coll. Card., 41(6), 961–965 (2003).
  • Malinin AI , AtarD, CallahanKP, McKenzie ME, Serebruany VL: Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur. J. Pharmacol., 462(1–3), 139–143 (2003).
  • Tantry US , BlidenKP, GurbelPA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.J. Am. Coll. Cardiol., 46(9), 1705–1709 (2005).
  • Harrison P , SegalH, BlasberyK, Furtado C, Silver L, Rothwell PM: Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke, 36(5), 1001–1005 (2005).
  • Serebruany VL , MalininAI, SaneDC: Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage?Am. J. Hematol., 72(4), 280–281 (2003).
  • Lennon MJ , GibbsNM, WeightmanWM, McGuireD, MichalopoulosN: A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients.J. Cardiothorac. Vasc. Anesth., 18(2), 136–140 (2004).
  • Gum PA , Kottke-MarchantK, PoggioEDet al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol., 88(3), 230–235 (2001).
  • Gawaz M , RufA, Pogatsa-MurrayGet al.: Incomplete inhibition of platelet aggregation and glycoprotein IIb–IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb–IIIa receptors. Thromb. Haemost., 83(6), 915–922 (2000).
  • Geisler T , LangerH, WydymusMet al.: Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur. Heart J., 27(20), 2420–2425 (2006).
  • Buonamici P , MarcucciR, MiglioriniAet al.: Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol., 49(24), 2312–2317 (2007).
  • Carville DG , SchleckserPA, GuyerKE, CorselloM, WalshMM: Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer.J. Extra Corpor. Technol., 30(4), 171–177 (1998).
  • Storey RF , WilcoxRG, HeptinstallS: Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.Circulation, 98(16), 1616–1621 (1998).
  • Karha J , BhattDL, Kottke-MarchantK: Use of Plateletworks™ vs. arachidonic acid aggregation to detect aspirin effect in healthy volunteers.J. Thromb. Haemost., 3(Suppl. 1), 1–8 (2005).
  • Craft RM , ChavezJJ, SniderCC, MuenchenRA, CarrollRC: Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients.J. Lab. Clin. Med., 145(6), 309–315 (2005).
  • Lau WC , WaskellLA, WatkinsPBet al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation, 107(1), 32–37 (2003).
  • Mobley JE , BreseeSJ, WorthamDC, Craft RM, Snider CC, Carroll RC: Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. Cardiol., 93(4), 456–458 (2004).
  • Lakkis NM , GeorgeS, ThomasE, AliM, GuyerK, CarvilleD: Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors.Catheter. Cardiovasc. Interv., 53(3), 346–351 (2001).
  • White MM , KrishnanR, KueterTJ, Jacoski MV, Jennings LK: The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB–IIIa antagonists. J. Thromb. Thrombolysis., 18(3), 163–169 (2004).
  • Ray MJ , WaltersDL, BettN, CameronJ, WoodP, AroneyC: Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention.Catheter. Cardiovasc. Interv., 62(2), 150–154 (2004).
  • Smit JJ , ErnstNM, SlingerlandRJet al.: Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome. Am. Heart J., 151(5), 1109–1114 (2006).
  • Favaloro EJ : Clinical application of the PFA-100.Curr. Opin. Hematol., 9(5), 407–415 (2002).
  • Mammen EF , CompPC, GosselinRet al.: PFA-100 system: a new method for assessment of platelet dysfunction. Semin. Thromb. Hemost., 24(2), 195–202 (1998).
  • Kottke-Marchant K , PowersJB, BrooksL, KunduS, ChristieDJ: The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).Clin. Appl. Thromb. Hemost., 5(2), 122–130 (1999).
  • Watala C , GolanskiJ, RozalskiMet al.: Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100? Thromb. Res., 109(5–6), 299–306 (2003).
  • Frossard M , FuchsI, LeitnerJMet al.: Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation, 110(11), 1392–1397 (2004).
  • Fuchs I , FrossardM, SpielA, RiedmullerE, LaggnerAN, JilmaB: Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.J. Thromb. Haemost. (2006).
  • Chakroun T , GerotziafasG, RobertFet al.: In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br. J. Haematol., 124(1), 80–85 (2004).
  • Haubelt H , AndersC, VogtA, HoerdtP, SeyfertUT, HellsternP: Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals.Br. J. Haematol., 130(5), 759–767 (2005).
  • Golanski J , PlutaJ, BaraniakJ, WatalaC: Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists – in vitro experience.Clin. Chem. Lab Med., 42(1), 25–29 (2004).
  • Hezard N , MetzD, NazeyrollasP, Droulle C, Potron G, Nguyen P: PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb. Res., 108(1), 43–47 (2002).
  • Coleman JL , WangJC, SimonDI: Determination of individual response to aspirin therapy using the accumetrics Ultegra RPFA-ASA system.Point of Care, (3), 77–82 (2004).
  • Golanski J , ChizynskiK, GolanskiR, WatalaC: [Use of platelet function analyzer PFA-100 and whole blood aggregometry to monitor blood platelet sensitivity to acetylsalicylic acid (aspirin). Is it possible to reliably monitor antiplatelet treatment using routine laboratory diagnostic methods?].Pol. Arch. Med. Wewn., 104(1), 355–361 (2000).
  • Homoncik M , JilmaB, HergovichN, StohlawetzP, PanzerS, SpeiserW: Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100.Thromb. Haemost., 83(2), 316–321 (2000).
  • Sambola A , HerasM, EscolarGet al.: The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets, 15(7), 439–446 (2004).
  • Angiolillo DJ , Fernandez-OrtizAet al., Bernardo E : Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am. J. Cardiol., 97(1), 38–43 (2006).
  • Coakley M , SelfR, MarchantW, MackieI, MallettSV, MythenM: Use of the Platelet Function Analyser (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease.Anaesthesia, 60(12), 1173–1178 (2005).
  • Macchi L , ChristiaensL, BrabantSet al.: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res., 107(1–2), 45–49 (2002).
  • Andersen K , HurlenM, ArnesenH, Seljeflot I: Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res., 108(1), 37–42 (2002).
  • Abaci A , CaliskanM, BayramFet al.: A new definition of aspirin non-responsiveness by Platelet Function Analyzer-100 and its predictors. Platelets, 17(1), 7–13 (2006).
  • Alberts MJ , BergmanDL, MolnerE, JovanovicBD, UshiwataI, TeruyaJ: Antiplatelet effect of aspirin in patients with cerebrovascular disease.Stroke, 35(1), 175–178 (2004).
  • Roller RE , DorrA, UlrichS, PilgerE: Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100.J. Thromb. Haemost., 13(4), 277–281 (2002).
  • Gianetti J , ParriMS, SbranaSet al.: Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb. Res., 118(4), 487–493 (2005).
  • Hayward CP , HarrisonP, CattaneoM, Ortel TL, Rao AK: Platelet Function Analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. J. Thromb. Haemost., 4(6), 1432 (2006).
  • Grau AJ , ReinersS, LichyC, BuggleF, Ruf A: Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke, 34(4), 849–854 (2003).
  • Raman S , JilmaB: Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100.J. Thromb. Haemost., 2(12), 2278–2279 (2004).
  • Van der Planken MG , ClaeysMJet al., Vertessen FJ : Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb. Res., 111(3), 159–164 (2003).
  • Hezard N , MetzD, NazeyrollasPet al.: Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb. Haemost., 83(4), 540–544 (2000).
  • Madan M , BerkowitzSD, ChristieDJet al.: Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am. Heart J., 141(2), 226–233 (2001).
  • Coller BS , LangD, ScudderLE: Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.Circulation, 95, 860–867 (1997).
  • Smith JW , SteinhublSR, LincoffAMet al.: Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation, 99(5), 620–625 (1999).
  • Kereiakes DJ , MuellerM, HowardWet al.: Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J. Thromb. Thrombolysis, 7(3), 265–276 (1999).
  • Wheeler GL , BradenGA, SteinhublSRet al.: The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am. Heart J., 143(4), 602–611 (2002).
  • Malinin A , PokovA, SperglingMet al.: Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb. Res., 119(3), 277–284 (2006).
  • von Beckerath N , Pogatsa-MurrayG, WieczorekA, SibbingD, SchomigA, KastratiA: Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness.Thromb. Haemost., 95(5), 910–911 (2006).
  • Wang JC , Aucoin-BarryD, ManuelianDet al.: Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am. J. Cardiol., 92(12), 1492–1494 (2003).
  • Chen WH , LeePY, NgW, TseHF, LauCP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.J. Am. Coll. Cardiol., 43(6), 1122–1126 (2004).
  • Lev EI , PatelRT, MareshKJet al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J. Am. Coll. Cardiol., 47(1), 27–33 (2006).
  • van Werkum JW , van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM: A head-to-head comparison between the VerifyNowP2Y12-assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective PCI. J. Thromb. Haemost., 4(11), 2516–2518 (2006).
  • Neumann FJ , HochholzerW, Pogatsa-MurrayG, SchomigA, GawazM: Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.J. Am. Coll. Cardiol., 37(5), 1323–1328 (2001).
  • Harder S , KlinkhardtU, GraffJet al.: In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests. Thromb. Res., 102(1), 39–48 (2001).
  • Matzdorff AC , KuhnelG, Kemkes-MatthesB, VossR: Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.J. Thromb. Thrombolysis, 12(2), 129–139 (2001).
  • Steinhubl SR , TalleyJD, BradenGAet al.: Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation, 103(21), 2572–2578 (2001).
  • Varon D , DardikR, ShenkmanBet al.: A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb. Res., 85(4), 283–294 (1997).
  • Weiss HJ , TurrittoVT, BaumgartnerHR: Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. Shear rate dependent decrease of adhesion in von Willebrand‘s disease and Bernard–Soulier Syndrome.J. Lab. Clin. Med., 92, 750–764 (1978).
  • Ikeda Y , HandaM, KawanoKet al.: The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J. Clin. Invest, 87, 1234–1240 (1991).
  • Savion N , VaronD: Impact – the cone and plate(let) analyzer: testing platelet function and anti-platelet drug response.Pathophysiol. Haemost. Thromb., 35(1–2), 83–88 (2006).
  • Shenkman B , SavionN, DardikR, Tamarin I, Varon D: Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb. Res., 99(4), 353–361 (2000).
  • Varon D , LashevskiI, BrennerBet al.: Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am. Heart J., 135(5 Pt 2 Su), S187–S193 (1998).
  • Shenkman B , SchneidermanJ, TamarinI, Kotev-EmethS, SavionN, VaronD: Testing the effect of GPIIb–IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods.Thromb. Res., 102(4), 311–317 (2001).
  • Osende JI , FusterV, LevEIet al.: Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation, 103(11), 1488–1491 (2001).
  • Hartert H : Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren.Klin. Wochenschr., 26, 577–583 (1948).
  • Rivard GE , Brummel-ZiedinsKE, Mann KG, Fan L, Hofer A, Cohen E: Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J. Thromb. Haemost., 3(9), 2039–2043 (2005).
  • Caprini JA , TraversoCI, ArcelusJI: Perspectives on thromboelastography.Semin. Thromb. Hemost., 21(Suppl. 4), 91–93 (1995).
  • Spiess BD : Thrombelastography and cardiopulmonary bypass.Semin. Thromb. Hemost., 21(Suppl. 4), 27–33 (1995).
  • Kang Y : Thrombelastography in liver transplantation.Semin. Thromb. Hemost., 21(Suppl. 4), 34–44 (1995).
  • Gillies BSA : Thrombelastography and liver transplantation.Semin. Thromb. Hemost., 21(Suppl. 4), 45–49 (1995).
  • McCrath DJ , CerboniE, FrumentoRJ, HirshAL, Bennett-GuerreroE: Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction.Anesth. Analg., 100(6), 1576–1583 (2005).
  • Tantry US , BlidenKP, GurbelPA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.J. Am. Coll. Cardiol., 46(9), 1705–1709 (2005).
  • Gurbel PA , BlidenKP, GuyerK, Aggarwal N, Tantry US: Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb. Res., 119(5), 563–570 (2006).
  • Khurana S , MattsonJC, WestleyS, O‘NeillWW, TimmisGC, SafianRD: Monitoring platelet glycoprotein IIb/IIIa–fibrin interaction with tissue factor-activated thromboelastography.J. Lab. Clin. Med., 130(4), 401–411 (1997).
  • Jernberg T , PayneCD, WintersKJet al.: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J., 27(10), 1166–1173 (2006).
  • Wiviott SD , AntmanEM, WintersKJet al.: Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation, 111(25), 3366–3373 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.